{"filings":[{"id":95367,"accession_number":"0001193125-26-210379","cik":1778129,"company_name":"TerrAscend Corp.","ticker":"TSNDF","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TerrAscend Q1 2026: revenue $65.5M, adj EBITDA $17.4M, 15th consecutive positive cash flow","event_type":"earnings","confidence":"high","bullets":["Net revenue $65.5M, +1.9% YoY; gross margin 52.8% vs 53.9% a year ago.","GAAP net loss from cont ops $6.8M vs $7.7M YoY; Adj EBITDA $17.4M (26.5% margin).","Net cash from cont ops $8.7M; free cash flow $7.8M; 15th straight quarter positive ops cash flow.","U.S. medical cannabis rescheduled to Schedule III post-quarter, eliminating 280E tax on medical cannabis.","Appointed Eric Jackson as CFO effective April 2026; executed NCIB repurchases of 115k shares at ~$0.66."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":65539000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95366,"accession_number":"0001193125-26-179245","cik":1778129,"company_name":"TerrAscend Corp.","ticker":"TSNDF","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TerrAscend prelim Q1 net revenue $65.5M, gross margin 52.8%, cash flow positive","event_type":"earnings","confidence":"high","bullets":["Net revenue of $65.5M from continuing operations, up from $64.3M in Q1 2025.","Gross profit margin of 52.8% exceeded internal targets; G&A expenses flat QoQ.","15th consecutive quarter of positive cash flow from operations.","Executive Chairman cited medical cannabis rescheduling and strong balance sheet.","Earnings conference call scheduled for May 7, 2026 at 8:00 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":65539000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95365,"accession_number":"0001193125-26-158998","cik":1778129,"company_name":"TerrAscend Corp.","ticker":"TSNDF","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"TerrAscend appoints Eric Jackson as CFO, effective April 27, 2026","event_type":"leadership","confidence":"high","bullets":["Base salary of $450,000; annual bonus target of 60% of base salary, guaranteed pro-rata for 2026.","Annual RSUs valued up to 75% of base salary; initial option grant of 300,000 common shares vesting over 4 years.","Jackson previously EVP/CFO at American Signature for 8+ years and spent 14+ years at L Brands.","Severance includes 12-month salary plus accelerated pro-rata vesting on termination without cause or for good reason.","Non-competition and non-solicitation covenants for 12 months post-termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108396,"accession_number":"0001193125-26-104330","cik":1778129,"company_name":"TerrAscend Corp.","ticker":"TSNDF","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TerrAscend Q4 revenue $66.1M, net loss narrows to $0.5M; FY2025 revenue $260.6M down 2.8% YoY","event_type":"earnings","confidence":"high","bullets":["GAAP net loss from continuing ops $0.5M in Q4 vs $9.9M in Q3; FY net loss $24.5M vs $20.9M in 2024.","Adjusted EBITDA from continuing ops $16.7M (25.2% margin) in Q4, $67.8M (26.0% margin) for FY.","Net cash from ops $8.3M in Q4, $33.9M for FY; free cash flow $6.6M Q4, $25.3M FY.","Completed $79M debt refinancing with $35M uncommitted facility for M&A; Michigan exit advanced.","Expanded retail in NJ via Union Chill; entered Ohio with Ratio Cannabis acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124836,"accession_number":"0001193125-25-335988","cik":1778129,"company_name":"TerrAscend Corp.","ticker":"TSNDF","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["3.02","7.01","9.01"],"status":"ready","headline":"TerrAscend closes $13M option to buy 35% of Union Chill NJ dispensary; accretive to EBITDA","event_type":"m_and_a","confidence":"high","bullets":["Total consideration $13M: $9M convertible notes (6.5%, due 2029) plus $4M cash on option exercise.","Union Chill generates >$11M annualized revenue; expected immediately accretive to EBITDA and cashflow.","Expands NJ retail to four dispensaries; upon full exercise, total consolidated footprint reaches 20.","Notes convertible at $1.89/share, only in entirety; prepayment allowed in $50K increments with 30-day notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124835,"accession_number":"0001193125-25-268109","cik":1778129,"company_name":"TerrAscend Corp.","ticker":"TSNDF","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TerrAscend Q3 revenue flat at $65.1M; gross margin up to 52.1%, adjusted EBITDA $17M","event_type":"earnings","confidence":"high","bullets":["Net revenue $65.1M (flat YoY); gross margin 52.1% (+110bps YoY). GAAP net loss $9.9M vs $15.8M a year ago.","Adjusted EBITDA from continuing ops $17.0M (26.1% margin) vs $16.9M in Q3 2024.","Net cash from ops $7.1M, free cash flow $4.9M – 13th consecutive quarter of positive cash from ops.","Completed $79M non-dilutive debt refinancing with added $35M uncommitted term facility for M&A.","Board authorized $10M share repurchase program over 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":194410000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141536,"accession_number":"0000950170-25-105046","cik":1778129,"company_name":"TerrAscend Corp.","ticker":"TSNDF","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TerrAscend Q2 net rev $65M, gross margin 51.1%; exits Michigan, completes $79M refinancing","event_type":"earnings","confidence":"high","bullets":["Net revenue $65.0M (down 3.3% YoY); gross profit margin improved to 51.1% from 49.6%.","GAAP net loss from continuing ops $6.4M (vs $6.3M loss YoY); adjusted EBITDA $16.0M (24.6% margin).","12th consecutive quarter positive cash flow from continuing ops ($7.3M); 8th consecutive positive free cash flow ($5.0M).","Announced exit from Michigan market; plans to sell assets in H2 2025 to pay down debt.","Subsequent to quarter end, closed $79M non-dilutive refinancing extending maturities to late 2028; additional $35M for M&A."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":129309000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141535,"accession_number":"0000950170-25-094711","cik":1778129,"company_name":"TerrAscend Corp.","ticker":"TSNDF","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["1.01","1.02","2.03","7.01","9.01"],"status":"ready","headline":"TerrAscend closes $79M debt upsize at 12.75%, retires $68M Pelorus loan, extends maturity to Aug 2028","event_type":"debt","confidence":"high","bullets":["Closed $79M upsize to existing senior secured syndicated term loan; $68M used to retire Pelorus Term Loan and other debt.","Loan carries 12.75% interest, matures August 2028, no prepayment penalties, and no warrants issued.","Additional uncommitted $35M facility available for M&A; no material debt maturing until late 2028.","Executive Chairman Jason Wild invested ~US$1.6M as part of the loan syndicate; constitutes a related party transaction.","Lead lender is FocusGrowth Asset Management; loan is guaranteed by TerrAscend and is non-dilutive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159385,"accession_number":"0000950170-25-091718","cik":1778129,"company_name":"TerrAscend Corp.","ticker":"TSNDF","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"TerrAscend exits Michigan market; will sell 4 cultivation facilities, 20 dispensaries","event_type":"other_material","confidence":"high","bullets":["Net proceeds from asset sales to be used to pay down Company debt.","Workforce reduction of ~21% (approx. 250 employees) expected by end of Q3 2025.","Michigan operations will be reported as discontinued operations starting Q2 2025.","Post-exit, TerrAscend will operate 19 dispensaries and 4 facilities across 5 states and Toronto.","Company anticipates improved consolidated gross margin, adjusted EBITDA, and cash flow conversion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159384,"accession_number":"0000950170-25-089492","cik":1778129,"company_name":"TerrAscend Corp.","ticker":"TSNDF","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"TerrAscend shareholders approve option repricing for CEO, CFO; CFO resignation confirmed","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment of 3,706,250 stock options held by CEO Ziad Ghanem, CFO Keith Stauffer, and CLO Lynn Gefen, reducing exercise price to 5-day VWAP on TSX before June 24, 2025.","Repricing conditional on each insider serving 12 months from June 24; CFO Stauffer resigned effective July 18, 2025, and will not meet service requirement.","All five director nominees elected: Craig Collard, Kara DioGuardi, Ira Duarte, Ed Schutter, Jason Wild.","Auditor MNP LLP re-appointed; option amendment passed with 49.8M votes for and 12.8M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159383,"accession_number":"0000950170-25-080387","cik":1778129,"company_name":"TerrAscend Corp.","ticker":"TSNDF","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["3.02","5.02","7.01","9.01"],"status":"ready","headline":"TerrAscend CFO Keith Stauffer to resign effective July 18, 2025; issues 5.46M shares for Apothecarium acquisition","event_type":"leadership","confidence":"high","bullets":["CFO Keith Stauffer resigns effective July 18, 2025 to pursue opportunity outside cannabis industry.","Alisa Campbell, SVP Corporate Finance, to lead finance on interim basis; permanent CFO search underway.","Company issued 5,457,898 common shares at $0.38/sh ($2.07M) to complete remaining 50.1% Apothecarium acquisition.","Stauffer receives pro-rata RSU vesting; will remain through transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}